Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models

Resistance to targeted EGFR inhibitors is likely to develop in EGFR mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detection of heterogeneous mechanisms of resistance within...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Res
Hlavní autoři: Eberlein, Catherine A., Stetson, Daniel, Markovets, Aleksandra A., Al-Kadhimi, Katherine J., Lai, Zhongwu, Fisher, Paul R., Meador, Catherine B., Spitzler, Paula, Ichihara, Eiki, Ross, Sarah J., Ahdesmaki, Miika J., Ahmed, Ambar, Ratcliffe, Laura E., Christey O’Brien, Elizabeth L., Barnes, Claire H., Brown, Henry, Smith, Paul D., Dry, Jonathan R., Beran, Garry, Thress, Kenneth S., Dougherty, Brian, Pao, William, Cross, Darren A. E.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4605607/
https://ncbi.nlm.nih.gov/pubmed/25870145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-3167
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky